Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Main Article Content

Christos C Zouboulis
Martin M Okun
Robert Gniadecki
Peter A Foley
Charles Lynde
Jamie Weisman
Piyalal Karunaratne
David A Williams


adalimumab, hidradenitis suppurativa, therapeutics


Abstract Not Available

Disclosures: Study supported by AbbVie.

Most read articles by the same author(s)

1 2 > >>